Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $50.27, while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| USIG | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $52.69 | $164.28 |
52-Week Low | $50.18 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USIG is trading at $50.32, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments, with the latest being $0.21 per share. A key development is AM Best's affirmation of credit ratings for USIG subsidiaries following a transaction with Tiptree Inc., as reported by Business Wire on July 30, 2026.
The outlook is cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may arise from stable dividend payments and institutional interest, such as Bank of New York Mellon Corp increasing its stake. Risks include reliance on external financial data and market sentiment shifts.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
